Day One Biopharmaceuticals pany(US:DAWN)2024-10-30 20:01Revenue and Sales Performance - OJEMDA net product revenue reached $20.1 million in Q3 2024, a 145% increase from Q2 2024[2] - Quarterly prescriptions (TRx) for OJEMDA grew to 619 in Q3 2024, representing a 159% increase over Q2 2024[3] - License revenue from the sale of ex-U.S. commercial rights for tovorafenib was $73.7 million in Q3 2024[8] Expenses - Research and development expenses were $33.6 million in Q3 2024, compared to $33.2 million in Q3 2023[9] - Selling, general and administrative expenses increased to $29.0 million in Q3 2024 from $18.3 million in Q3 2023[10] Profitability - Net income for Q3 2024 was $37.0 million, compared to a net loss of $46.2 million in Q3 2023[11] Financial Position - Cash, cash equivalents, and short-term investments totaled $558.4 million as of September 30, 2024[11] Pipeline and Development - Day One plans to advance its pipeline, including the DAY301 program, expected to enter the clinic in the coming months[2] - An exclusive licensing agreement with Ipsen for tovorafenib outside the U.S. included approximately $111 million upfront and potential milestone payments of up to $350 million[6] - The pivotal Phase 3 FIREFLY-2/LOGGIC trial for tovorafenib continues to enroll patients across multiple regions with over 100 sites activated[5]